Richard William Scalzo Sells 1,112 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock

Posted by Francis Steltz on Jun 25th, 2026

Crescent Biopharma, Inc. (NASDAQ:CBIO – Get Free Report) CFO Richard William Scalzo sold 1,112 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $17.99, for a total value of $20,004.88. Following the completion of the transaction, the chief financial officer directly owned 20,298 shares of the company’s stock, valued at approximately $365,161.02. The trade was a 5.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Crescent Biopharma Price Performance

Shares of NASDAQ CBIO opened at $17.36 on Thursday. The stock has a market capitalization of $478.44 million, a P/E ratio of -1.59 and a beta of 1.16. Crescent Biopharma, Inc. has a 1-year low of $8.72 and a 1-year high of $27.41. The business has a fifty day moving average price of $19.81 and a 200 day moving average price of $15.07.

Crescent Biopharma (NASDAQ:CBIO – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.15. The company had revenue of $1.04 million for the quarter, compared to the consensus estimate of $0.36 million. As a group, equities research analysts anticipate that Crescent Biopharma, Inc. will post -3.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on CBIO shares. HC Wainwright lowered their price target on shares of Crescent Biopharma from $25.00 to $22.00 and set a “buy” rating on the stock in a report on Monday, March 2nd. Stifel Nicolaus set a $29.00 target price on shares of Crescent Biopharma in a research report on Thursday, February 26th. Wall Street Zen upgraded shares of Crescent Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings upgraded shares of Crescent Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.00.

Get Our Latest Stock Analysis on Crescent Biopharma

Institutional Investors Weigh In On Crescent Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jefferies Financial Group Inc. boosted its holdings in Crescent Biopharma by 279.1% in the third quarter. Jefferies Financial Group Inc. now owns 102,714 shares of the biopharmaceutical company’s stock worth $1,221,000 after acquiring an additional 75,618 shares in the last quarter. NEXTBio Capital Management LP purchased a new stake in shares of Crescent Biopharma during the fourth quarter worth about $4,422,000. BVF Inc. IL increased its holdings in shares of Crescent Biopharma by 98.1% during the fourth quarter. BVF Inc. IL now owns 2,748,763 shares of the biopharmaceutical company’s stock valued at $32,600,000 after acquiring an additional 1,360,900 shares in the last quarter. Fcpm Iii Services B.V. acquired a new position in shares of Crescent Biopharma during the fourth quarter valued at about $19,899,000. Finally, Quadrature Capital Ltd purchased a new position in shares of Crescent Biopharma in the 4th quarter valued at approximately $157,000. 75.19% of the stock is currently owned by hedge funds and other institutional investors.

Crescent Biopharma Company Profile

(Get Free Report)

Crescent Biopharma, Inc (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth.

The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis.